Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
Immunotherapy

Rahul Aggarwal, ESMO 2021: Ceralasertib in ARID1A-deficient and ARID1A-intact Advanced Solid Tumour Malignancies

Copy Link
Published Online: Oct 11th 2021

touchONCOLOGY joins Prof Rahul Aggarwal (UCSF School of Medicine, San Francisco, CA, USA), to discuss the interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumour malignancies.

Questions
1. Could you tell us a little about ARID1A alterations in solid tumours and potential therapeutic targets in ARID1A-mutated tumours? (00:15-01:12)
2. What is the rationale for the use of ceralasertib in patients harbouring ARID1A-deficient solid tumours? (01:12-02:10)
3. What were the aims and design of the study you are presenting? (02:10-03:20)
4. How well were the clinical endpoints achieved? (03:20-04:10)
5. What will stage 2 of the study entail and which patients will be eligible? (04:10-04:45)

Disclosures: UCSF School of Medicine has received research funding from AstraZeneca.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the ESMO 2021 Annual Meeting.

Share this Video
Related Videos In Immunotherapy
Immunotherapy
Developed by Touch
Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy
Watch Time: 15 mins

We are delighted to speak with Dr Robin Foà, one of our Editorial Board members for touchREVIEWS in Oncology & Haematology, to discuss the sustainability and accessibility of CAR-T Cell Therapy as well as the challenges associated with this treatment. Questions Could you give us a brief overview of the current approval status of CAR-T […]

Immunotherapy
Michael Atkins: Safe and Effective Use of Immune Checkpoint Inhibitors in Patients with Cancer

Dr Michael Atkins (MedStar Georgetown University Hospital, Washington, DC, USA) shares three areas for development to help improve the safe and effective use of immune checkpoint inhibitors. 1. Having a rational approach to stopping therapy (00:50-02:20) 2. An improved understanding of toxicity and response (02:20-04:25) 3. The role of combining and sequencing immunotherapy with standard […]

Immunotherapy
Lyudmila A Bazhenova, WCLC 2021: Challenges of Widespread Immunotherapy

touchONCOLOGY joins Prof Lyudmila A Bazhenova (University of California San Diego, CA) at WCLC 2021 to discuss the challenges faced when expanding patients receiving immunotherapy for the treatment of non-small cell lung cancer. Questions 1. What has been the impact of immunotherapy in the treatment of non-small cell lung cancer (NSCLC)? (00:12-00:51) 2. What are […]

Trending In Immunotherapy:

Robin Foà: Sustainability and Accessibility of CAR-T Cell Therapy
Immunotherapy
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72